Aparna R. Parikh

机构：Harvard University, Massachusetts General Hospital, Center for Cancer Research · ORCID：0000-0002-5245-7841

发表论文 585 篇 · 总被引 9003 次 · h-index 37

代表论文

• Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors (2026 · New England Journal of Medicine · 被引 23)
• Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors (2025 · Cancer Research · 被引 23)
• Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases (2025 · Annals of Surgical Oncology · 被引 12)
• Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators (2026 · Cancer Discovery · 被引 6)
• Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti–CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC. (2025 · Journal of Clinical Oncology · 被引 6)
• Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer (2025 · JCO Precision Oncology · 被引 5)